Patient info Search Menu

Carbaglu 200 mg dispersible tablets – patient leaflet, side effects, dosage

Status:
Prescription only (POM) Key facts
Medicine strength:
200 mg
Contains active substance:

Patient leaflet - Carbaglu 200 mg dispersible tablets

1. What Carbaglu is and what it is used for

Carbaglu can help eliminating excessive ammonia plasma levels (elevated ammonia level in the blood). Ammonia is especially toxic for the brain and leads, in severe cases, to reduced levels of consciousness and to coma.

Hyperammonaemia may be due to

  • the lack of a specifi c liver enzyme N- acetylglutamate synthase. Patients with this rare disorder are not able to eliminate nitrogen waste, which builds up after eating protein.

This disorder persists during the entire life of the aff ected patient and therefore the need for this treatment is lifelong.

  • isovaleric acidaemia, methylmalonic acidaemia or propionic acidaemia. Patients suff ering from one of these disorders need treatment during the hyperammonaemia crisis.

2. What you need to know before you take Carbaglu

Do not take Carbaglu

If you are allergic to carglumic acid or any of the other ingredients of this medicine (listed in section 6). Do not take Carbaglu during breast-feeding

Warnings and precautions

Talk to your doctor or pharmacist before taking Carbaglu.

Carbaglu treatment should be initiated under the supervision of a physician experienced in the treatment of metabolic disorders.

Your doctor will evaluate your individual responsiveness to carglumic acid before initiating any long term treatment. The dose should be individually adjusted in order to maintain normal ammonia plasma levels.

Your doctor may prescribe supplemental arginine or restrict your protein intake.

In order to follow-up your condition and your treatment, your doctor may examine your liver, your kidneys, your heart and your blood on a regular basis.

Other medicines and Carbaglu

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Carbaglu with food and drink

Carbaglu must be taken orally before meals or feedings.

The tablets must be dispersed in a minimum of 5 to 10 ml of water and taken immediately. The suspension has a slightly acidic taste.

Pregnancy and breast-feeding

The eff ects of Carbaglu on pregnancy and the unborn child are not known.

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

The excretion of carglumic acid into breast milk has not been studied in women. Nevertheless, as carglumic acid has been shown to be present in the milk of lactating rats with potential toxic eff ects for their fed pups, you should not breast feed your baby if you are taking Carbaglu.

Driving and using machines

Eff ects on the ability to drive and use machines are not known.

3. How to take Carbaglu

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

The usual dose:

The initial daily dose is usually 100 mg per kilogram of body weight, up to a maximum of 250 mg per kilogram of body weight (for example, if you weight 10kg, you should take 1g per day, or 5 tablets), For patients suff ering from N-acetylglutamate synthase defi ciency, in the long term, the daily dose usually ranges from 10 mg to 100 mg per kilogram of body weight.

Your doctor will determine the dose suitable to you in order to maintain normal ammonia levels in your blood.

Carbaglu should ONLY be administered by mouth or via a feeding tube into the stomach (using a syringe, if necessary).

When the patient is in hyperammonaemic coma, Carbaglu is administered by fast push through a syringe via the tube set up and used to feed you.

Tell your doctor in case you are suffering from renal impairement. Your daily dose should be reduced.

If you take more Carbaglu than you should

Ask your doctor or pharmacist for advice.

If you forget to take Carbaglu

Do not take a double dose to make up for forgotten doses.

If you stop taking Carbaglu

Do not stop Carbaglu without informing your doctor.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

4. Possible effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The following side effects were reported as follows: very common (may affect more than 1 in 10 people), common (may affect up to 1 in 10 people), uncommon (may affect up to 1 in 100 people), rare (may affect up to 1 in 1,000 people), very rare (may affect up to 1 in 10,000 people) and not known (frequency cannot be estimated from the available data).

  • Common: increased sweating
  • Uncommon: bradycardia (decreased frequency of the heart), diarrhoea, fever, increased transaminases, vomiting
  • Not known: rash

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store carbaglu

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the tablet container after EXP. The expiry date refers to the last day of that month.

Store in a refrigerator (2°C – 8°C).

After first opening of the container: do not refrigerate, do not store above 30°C.

Keep the container tightly closed in order to protect from moisture.

Write the date of opening on the tablet container. Discard 3 months after first opening.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Carbaglu contains

  • The active substance is carglumic acid. Each tablet contains 200 mg of carglumic acid.
  • The other ingredients are microcrystalline cellulose, sodium laurilsulfate, hypromellose, croscarmellose sodium, silica colloidal anhydrous, sodium stearyl fumarate.

What Carbaglu looks like and contents of the pack

Carbaglu 200mg tablet is a bar-shaped tablet, with 4 punches on one side with 3 break-mark sides. Carbaglu is presented in a plastic container of 5, 15 and 60 tablets which is closed with a child resistant cap.

Marketing Authorisation Holder

Recordati Rare Diseases

Tour Hekla

52, avenue du Général de Gaulle

F-92800 Puteaux

France

Tel: + 33 1 4773 6458

Fax: + 33 1 4900 1800

Manufacturer

Recordati Rare Diseases

Tour Hekla

52, avenue du Général de Gaulle F-92800 Puteaux

France

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder. United Kingdom

Recordati Rare Diseases UK Ltd.

Tel: +44 (0)1491 414333

This leaflet was last approved in 12/2024

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PLGB 15266/0019

MHRA data as of 13 October 2026

What the sections and the side effect frequencies mean: How to read a patient leaflet

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Carbaglu 200 mg dispersible tablets

What these facts mean

Prescription needed?? Yes, prescription-only medicine (POM)
Active substance? Carglumic acid
Strength? 200 mg
Pharmaceutical form? Dispersible tablet
The tablets are white and elongated with three score marks and engraved on one side. The tablet can be divided into equal doses.
How is it taken? Oral, Gastroenteral
Excipients? Microcrystalline cellulose, sodium laurilsulfate, hypromellose, croscarmellose sodium, silica colloidal anhydrous, sodium stearyl fumarate
Pack sizes 5 tablet, 60 tablet
Is it available?? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life? 36 months
After first opening of the tablet container: 3 months
Storage Store in a refrigerator (2°C – 8°C)
After first opening of the tablet container: Do not refrigerate.
Do not store above 30°C.
Keep the container tightly closed in order to protect from moisture.
Drug group (ATC)? Amino acids and derivatives
  1. A Alimentary tract and metabolism drugs
    1. A16 Other alimentary tract and metabolism products
      1. A16A Other alimentary tract and metabolism products
        1. A16AA Amino acids and derivatives
          1. A16AA05 carglumic acid
Marketing authorisation? PLGB 15266/0019 (first authorised 1 January 2021)
Marketing authorisation holder? Recordati Rare Diseases
Codes? GTIN 3663502000366, 3663502000380 · BNF 09080100

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 11.1.0 of 9 November 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.